23andMe’s CEO files plan to take company private

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) 

DNA testing company 23andMe’s CEO Anne Wojcicki is looking to take the company private, according to a Wednesday securities filing.

Wojcicki, the filing said, told a special committee to the board of directors that she plans to speak with partners and other sources that could help finance the take-private, but would not support any “alternative transaction.”

The consumer genetics company, which also develops new medications, has struggled with its dual identity. 23andMe went public in 2o21 via a SPAC deal that valued the company at $3.5 billion and priced the company at $10 per share, though its stock has been trading for under a dollar per share since last fall.

It’s not alone in having a hard time building a sustainable DNA-testing…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks